Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Mediators of Inflammation, enter your email address in the box below.

Mediators of Inflammation
Volume 2015, Article ID 979526, 8 pages
http://dx.doi.org/10.1155/2015/979526
Clinical Study

Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy

Katerina Kondelkova,1 Lenka Borska,2 Ctirad Andrys,1 Jan Krejsek,1 Kvetoslava Hamakova,3 Simona Rendarova,3 Vit Rehacek,4 Jan Kremlacek,2 and Zdenek Fiala5

1Institute of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Sokolska 581, 50005 Hradec Kralove, Czech Republic
2Institute of Pathological Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Sokolska 581, 50005 Hradec Kralove, Czech Republic
3Department of Dermatology and Venereal Diseases, University Hospital Hradec Kralove, Sokolska 581, 50005 Hradec Kralove, Czech Republic
4Department of Transfusion Medicine, University Hospital Hradec Kralove, Sokolska 581, 50005 Hradec Kralove, Czech Republic
5Institute of Hygiene and Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Sokolska 581, 50005 Hradec Kralove, Czech Republic

Received 20 February 2015; Revised 11 May 2015; Accepted 31 May 2015

Academic Editor: Luca Cantarini

Copyright © 2015 Katerina Kondelkova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Enerbäck, “Soluble biomarkers in psoriasis,” European Journal of Dermatology, vol. 21, no. 6, pp. 844–850, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Cordiali-Fei, L. Bianchi, C. Bonifati et al., “Immunologic biomarkers for clinical and therapeutic management of psoriasis,” Mediators of Inflammation, vol. 2014, Article ID 236060, 11 pages, 2014. View at Publisher · View at Google Scholar
  3. E. Christophers, “Psoriasis—epidemiology and clinical spectrum,” Clinical and Experimental Dermatology, vol. 26, no. 4, pp. 314–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Baran, I. Flisiak, J. Jaroszewicz, and M. Świderska, “Serum adiponectin and leptin levels in psoriatic patients according to topical treatment,” Journal of Dermatological Treatment, 2015. View at Publisher · View at Google Scholar
  5. C. Ryan and B. Kirby, “Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities,” Dermatologic Clinics, vol. 33, no. 1, pp. 41–55, 2015. View at Publisher · View at Google Scholar
  6. L. Litvinova, D. Atochin, M. Vasilenko et al., “Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome,” Diabetology & Metabolic Syndrome, vol. 6, no. 1, p. 137, 2014. View at Publisher · View at Google Scholar
  7. M. Blüher and C. S. Mantzoros, “From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century,” Metabolism: Clinical and Experimental, vol. 64, no. 1, pp. 131–145, 2015. View at Publisher · View at Google Scholar
  8. H. Kwon and J. E. Pessin, “Adipokines mediate inflammation and insulin resistance,” Frontiers in Endocrinology, vol. 4, article 71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Coimbra and A. Santos-Silva, “Biomarkers of psoriasis severity and therapy monitoring,” World Journal of Dermatology, vol. 3, no. 2, pp. 15–27, 2014. View at Google Scholar
  10. A. Ctirad, B. Lenka, P. David et al., “Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level,” International Journal of Dermatology, vol. 47, no. 10, pp. 1011–1014, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. L. Orseth and T. G. Cropley, “What's in a name? Goeckerman therapy,” JAMA Dermatology, vol. 149, no. 12, p. 1409, 2013. View at Publisher · View at Google Scholar
  12. L. Borska, Z. Fiala, C. Andrys et al., “Goeckerman's regimen: genotoxic, pro-apoptotic, anti-inflamatory and anti-angiogenic effect,” in Dermatology Research. Focus on Acne, Melanoma, and Psoriasis, F. Columbus, Ed., pp. 141–165, Nova Science Publishers, Hauppauge, NY, USA, 2010. View at Google Scholar
  13. D. Ranna, C. Andrys, J. Krejsek et al., “Elevated levels of circulating biomarkers of cell death (nucleosomes) in the patients with plaque psoriasis treated with the Goeckerman regimen,” Bratislavske Lekarske Listy, vol. 115, no. 4, pp. 229–232, 2014. View at Publisher · View at Google Scholar
  14. M. L. Moscaliuc, M. M. Heller, E. S. Lee, and J. Koo, “Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis,” Journal of Dermatological Treatment, vol. 24, no. 1, pp. 34–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Agents Classified by the IARC Monographs, International Agency for Research on Cancer, Lyon, France, 2014.
  16. L. Borska, C. Andrys, J. Krejsek et al., “Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs,” Journal of Immunology Research, vol. 2014, Article ID 834389, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. IARC, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Radiation, vol. 100D, International Agency for Research on Cancer (IARC), Lyon, France, 2012.
  18. A. Hannuksela-Svahn, E. Pukkala, E. Läärä, K. Poikolainen, and J. Karvonen, “Psoriasis, its treatment, and cancer in a cohort of finnish patients,” The Journal of Investigative Dermatology, vol. 114, no. 3, pp. 587–590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. S. S. Wang, C. R. Flowers, M. E. Kadin et al., “Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project,” Journal of the National Cancer Institute: Monographs, vol. 2014, no. 48, pp. 66–75, 2014. View at Publisher · View at Google Scholar
  20. J. H. Roelofzen, K. K. Aben, P. C. van de Kerkhof, P. G. van der Valk, and L. A. Kiemeney, “Dermatological exposure to coal tar and bladder cancer risk: a case-control study,” Urologic Oncology, vol. 33, no. 1, pp. 19–22, 2015. View at Publisher · View at Google Scholar
  21. J. H. J. Roelofzen, K. K. H. Aben, U. T. H. Oldenhof et al., “No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema,” The Journal of Investigative Dermatology, vol. 130, no. 4, pp. 953–961, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. V. Paghdal and R. A. Schwartz, “Topical tar: back to the future,” Journal of the American Academy of Dermatology, vol. 61, no. 2, pp. 294–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Borska, C. Andrys, J. Krejsek et al., “Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 302528, 10 pages, 2014. View at Publisher · View at Google Scholar
  24. M. A. de Rie, A. Y. Goedkoop, and J. D. Bos, “Overview of psoriasis,” Dermatologic Therapy, vol. 17, no. 5, pp. 341–349, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. J. Oh, H. K. Lim, J. H. Choi, J. W. Lee, and N. I. Kim, “Serum leptin and adiponectin levels in Korean patients with psoriasis,” Journal of Korean Medical Science, vol. 29, no. 5, pp. 729–734, 2014. View at Publisher · View at Google Scholar
  26. M. Rajappa, S. Rathika, M. Munisamy, L. Chandrashekar, and D. M. Thappa, “Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 1, pp. 69–76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. K.-J. Zhu, C. Zhang, M. Li, C.-Y. Zhu, G. Shi, and Y.-M. Fan, “Leptin levels in patients with psoriasis: a meta-analysis,” Clinical and Experimental Dermatology, vol. 38, no. 5, pp. 478–483, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. C. Li, P. Krishnamoorthy, S. DerOhannessian et al., “Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors,” Clinical and Experimental Dermatology, vol. 39, no. 1, pp. 19–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Coimbra, H. Oliveira, F. Reis et al., “Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 12, pp. 1386–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Özdemir, M. Yüksel, H. Gökbel, N. Okudan, and I. Mevlitoğlu, “Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin,” The Journal of Dermatology, vol. 39, no. 5, pp. 443–448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. K.-J. Zhu, G. Shi, C. Zhang, M. Li, C.-Y. Zhu, and Y.-M. Fan, “Adiponectin levels in patients with psoriasis: a meta-analysis,” The Journal of Dermatology, vol. 40, no. 6, pp. 438–442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Corbetta, R. Angioni, A. Cattaneo, P. Becke-Peccoz, and A. Spada, “Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines,” European Journal of Endocrinology, vol. 154, no. 1, pp. 83–86, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Kawashima, K. Torii, T. Furuhashi et al., “Phototherapy reduces serum resistin levels in psoriasis patients,” Photodermatology Photoimmunology and Photomedicine, vol. 27, no. 3, pp. 152–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kondelkova, J. Krejsek, L. Borska et al., “Membrane and soluble Toll-like receptor 2 in patients with psoriasis treated by Goeckerman therapy,” International Journal of Dermatology, vol. 53, no. 11, pp. 512–517, 2014. View at Publisher · View at Google Scholar
  35. Z. Yan, H. Zhang, C. Maher et al., “Prenatal polycyclic aromatic hydrocarbon, adiposity, peroxisome proliferator-activated receptor (PPAR) γ methylation in offspring, grand-offspring mice,” PLoS ONE, vol. 9, no. 10, Article ID e110706, 2014. View at Publisher · View at Google Scholar
  36. P. Irigaray and D. Belpomme, “Basic properties and molecular mechanisms of exogenous chemical carcinogens,” Carcinogenesis, vol. 31, no. 2, pp. 135–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Irigaray, S. Lacomme, L. Mejean, and D. Belpomme, “Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons,” Toxicology Letters, vol. 187, no. 1, pp. 35–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Irigaray, V. Ogier, S. Jacquenet et al., “Benzo[a]pyrene impairs β-adrenergic stimulation of adipose tissue lipolysis and causes weight gain in mice: a novel molecular mechanism of toxicity for a common food pollutant,” The FEBS Journal, vol. 273, no. 7, pp. 1362–1372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Ortiz, B. Nakamura, X. Li, B. Blumberg, and U. Luderer, “Reprint of ‘in utero exposure to benzo[a]pyrene increases adiposity and causes hepatic steatosis in female mice, and glutathione deficiency is protective’,” Toxicology, vol. 230, no. 2, pp. 314–321, 2014. View at Publisher · View at Google Scholar